ATLANTA--(BUSINESS WIRE)--Holzer & Holzer, LLC announces that a class action lawsuit has been filed in the United States District Court for the District of Nevada on behalf of investors who purchased Galectin Therapeutics, Inc. (“Galectin” or the “Company”) (NASDAQ: GALT) securities between January 6, 2014 and July 28, 2014. The complaint alleges that during the relevant time period, Galectin issued false and misleading statements which, among other things, allegedly failed to disclose that Galectin utilized paid promoters to issue misleading statements about Galectin’s prospects, particularly with regard to the Company’s leading product candidate GR-MD-02. Galectin stock price declined dramatically following a series of articles accusing the Company of improper conduct in connection with promoting its experimental drug.
If you purchased Galectin securities between January 6, 2014 and July 28, 2014 and suffered substantial losses on those transactions, you are encouraged to contact Marshall P. Dees, Esq. via email at mdees@holzerlaw.com, or via toll-free telephone at (888) 508-6832, regarding your legal rights. There is a deadline of September 28, 2014 for interested investors to ask the court to be appointed as lead plaintiff for the case.
Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.